STOCKHOLM – Elotuzumab, pomalidomide, and dexamethasone improved progression-free survival and responses, compared with pom/dex alone in patients...
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
A triple-therapy regimen was well tolerated, with low rates of neutropenia both overall and in the lenalidomide-refractory subset of myeloma...
CHICAGO – The OPTIMISMM study examined patients who had received at least two prior cycles of lenalidomide.
CHICAGO – ASH guideline coauthor explains the evidence behind the group’s recent guidelines on bone-modifying agents in multiple myeloma.
The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.
The phase 1b/2 trial will begin enrollment in the second half of 2018.
From the Journals
The United States had more new cases and more deaths than any other country in 2016.
The FDA approved the drug in combination with VMP for patients who are ineligible for transplant.